What WHI E+P Actually Changes in Clinical Practice

At a glance

• Trial: Women's Health Initiative Estrogen Plus Progestin (WHI E+P)
• N: 16,608 postmenopausal women aged 50 to 79
• Intervention: Conjugated equine estrogens 0.625 mg/d + medroxyprogesterone acetate 2.5 mg/d
• Comparator: Matching placebo
• Duration: Planned for 8.5 years; stopped early at 5.2 years (mean follow-up)
• Primary endpoints: Coronary heart disease (primary benefit outcome), invasive breast cancer (primary safety outcome)
• Key result: Hazard ratio 1.26 (95% CI 1.00, 1.59) for CHD and 1.26 (95% CI 1.00, 1.59) for invasive breast cancer; global index exceeded preset stopping boundary

The Trial That Changed Everything, Then Got Misread

Before 2002, combined HRT was prescribed to millions of postmenopausal women partly on the assumption that it would prevent heart disease. Observational data from the Nurses' Health Study had suggested a cardioprotective effect. The WHI E+P arm was designed to test that hypothesis in a randomized, placebo-controlled setting. When the Data Safety Monitoring Board halted the trial early because the global index statistic crossed its predefined stopping boundary, the clinical world reacted with a binary message: HRT causes breast cancer and heart attacks. That framing was incomplete.

What the Methodology Actually Looked Like

The WHI E+P arm enrolled women between 1993 and 1998 across 40 U.S. clinical centers. The mean age at randomization was 63.3 years. Only 33.4% of participants were aged 50 to 59. This age distribution matters because the primary clinical question most women and their doctors care about, whether HRT is safe for managing menopausal vasomotor symptoms, applies mainly to women in their late 40s and 50s.

Adherence was another issue. By year 6, roughly 42% of women assigned to active treatment had stopped taking their pills, and about 10.7% of women in the placebo group had started taking hormones on their own. This crossover diluted the true effect in both directions.

The intervention itself was a single fixed-dose regimen: 0.625 mg/d CEE paired with 2.5 mg/d MPA. No dose titration, no alternative progestogens, no transdermal formulations. The FDA-approved prescribing information for Prempro reflects this specific combination, not the broader category of menopausal hormone therapy.

Results Beyond the Headlines

The hazard ratios from the primary publication tell a more nuanced story than what reached mainstream media.

A few things stand out. The absolute risk increases were small, on the order of 7 to 8 additional events per 10,000 person-years. The fracture reduction was the largest absolute effect in the entire trial. And the breast cancer hazard ratio just barely crossed 1.00 in the confidence interval, making it statistically borderline.

The Age Stratification That Matters Most

The WHI age-stratified reanalysis published in 2007 changed the clinical picture substantially. Among women aged 50 to 59, the CHD hazard ratio was 1.11 (95% CI 0.64, 1.94), statistically nonsignificant. Among women 70 to 79, it was 1.44 (95% CI 1.00, 2.07). The p-value for the age interaction trend was 0.08 for CHD, suggestive though not definitive.

For all-cause mortality in women aged 50 to 59, the hazard ratio was 0.69 (95% CI 0.44, 1.07). That point estimate favored active treatment. The cumulative 18-year follow-up data confirmed that neither all-cause mortality nor cardiovascular mortality differed significantly between the active and placebo groups over the long term, including after women stopped taking the medication.

These findings support what is now called the "timing hypothesis": HRT initiated close to menopause onset has a different risk-benefit profile than HRT started a decade or more after menopause.

Which Guidelines Actually Changed

The reaction to WHI E+P was not just media-driven. Professional societies issued updated position statements over the following years.

The Endocrine Society published a 2010 scientific statement that explicitly endorsed menopausal HRT for symptomatic women under 60, acknowledging the timing hypothesis while noting that the WHI data did not apply directly to women initiating therapy near menopause onset.

The North American Menopause Society (NAMS) revised its position statement multiple times. The 2022 NAMS position statement supports hormone therapy for women under 60 or within 10 years of menopause onset who have bothersome vasomotor symptoms, with no arbitrary duration limit. This is a direct course correction from the post-WHI era, when many clinicians capped HRT at 3 to 5 years.

The FDA updated Prempro labeling with a boxed warning referencing the WHI findings. That warning remains in effect. It states that estrogen plus progestin therapy should be prescribed at the lowest effective dose for the shortest duration consistent with treatment goals.

What Was NOT Tested

Several assumptions got folded into the WHI fallout that the trial never addressed.

Transdermal estradiol was not studied. The WHI used oral CEE. Observational and pharmacokinetic data suggest that transdermal estradiol avoids the hepatic first-pass effect that drives clotting factor changes. A large nested case-control study found that transdermal estrogen was not associated with increased venous thromboembolism risk, unlike oral formulations.

Micronized progesterone was not studied. MPA was the sole progestogen. The ESTHER study and the French E3N cohort data suggest that micronized progesterone may carry a lower breast cancer signal than MPA. This distinction is clinically important because many current prescribing patterns use transdermal estradiol plus oral micronized progesterone, a combination that was never part of WHI.

Symptomatic women were underrepresented. Only about 12.5% of WHI participants reported moderate-to-severe vasomotor symptoms at enrollment. The women with the strongest clinical indication for HRT were a minority of the study population.

How Prescribing Patterns Shifted, Then Partially Corrected

Between 2001 and 2003, HRT prescriptions in the U.S. dropped by roughly 50%. Many women who were doing well on therapy stopped abruptly, sometimes without tapering, because their physicians or they themselves interpreted the WHI results as an absolute contraindication.

By 2010, prescribing had stabilized at a lower level but the medical societies were already walking back the blanket avoidance. The shift happened in stages. First came acknowledgment that the WHI population was older than the typical HRT candidate. Then came the age-stratified reanalyses. Then came the guideline updates from NAMS and the Endocrine Society endorsing "window of opportunity" prescribing.

Today, the gap between guideline recommendations and real-world prescribing remains. Many primary care physicians still avoid HRT entirely because the WHI headlines were so dominant. A 2019 survey found that residency training in menopause management had declined markedly in the post-WHI era. The clinical implication: undertreated vasomotor symptoms became a widespread problem partly because of how the WHI results were communicated, not just because of what they found.

What This Trial Should Change in Your Conversation With Your Doctor

For a woman aged 50 to 59 with bothersome hot flashes and no personal history of breast cancer, the WHI data do not support avoiding HRT. The absolute risk increase in that age group was small and statistically nonsignificant for the outcomes that drove early stopping.

For a woman over 65 who has never used HRT, starting combined oral CEE + MPA specifically to prevent chronic disease is not supported. That was the question WHI answered most clearly.

For any woman considering HRT, the formulation matters. The WHI tested one regimen. Current practice frequently uses different estrogens (17-beta estradiol), different routes (transdermal patches or gels), and different progestogens (micronized progesterone). These choices carry different risk profiles that the WHI did not measure.

The FDA's current guidance on menopausal hormone therapy still references the WHI boxed warning, but the clinical interpretation of that warning has evolved substantially in professional practice guidelines.

Frequently asked questions

›Did the WHI prove that all HRT causes breast cancer?

No. The WHI E+P arm found a borderline-significant increase in invasive breast cancer with one specific regimen (oral CEE 0.625 mg + MPA 2.5 mg daily). The estrogen-only arm of the WHI, which studied CEE alone in women with prior hysterectomy, actually showed a reduced breast cancer risk over the follow-up period. Different progestogens and delivery routes were not tested.

›What was the average age of women in the WHI E+P trial?

The mean age at enrollment was 63.3 years. Only about one-third of participants were in the 50 to 59 age range, which is the group most likely to seek HRT for menopausal symptoms in clinical practice.

›Did the WHI study transdermal estrogen patches?

No. The WHI used only oral conjugated equine estrogens. Transdermal estradiol, which is now widely prescribed, was not included. Observational evidence suggests transdermal delivery carries lower thrombotic risk than oral formulations.

›Why was the WHI E+P trial stopped early?

The Data Safety Monitoring Board determined that the global index statistic, a composite of benefits and risks, had crossed its predefined stopping boundary. The breast cancer hazard ratio exceeded the preset threshold after a mean of 5.2 years of follow-up.

›What is the 'timing hypothesis' for HRT?

The timing hypothesis proposes that HRT initiated close to menopause onset (within 10 years or before age 60) has a neutral or potentially beneficial cardiovascular effect, while HRT started more than a decade after menopause may increase cardiovascular risk. The WHI age-stratified data are consistent with this pattern, though the trial was not powered to test it definitively.

›Do current guidelines recommend against HRT for menopausal symptoms?

No. Both NAMS and the Endocrine Society support HRT for symptomatic women under 60 or within 10 years of menopause, using the lowest effective dose. The post-WHI blanket avoidance of HRT is no longer consistent with current professional guidelines.

›Is micronized progesterone safer than MPA?

The WHI did not study micronized progesterone, so no randomized trial comparison exists. Observational data from European cohorts suggest that micronized progesterone may carry a lower breast cancer signal than MPA, but this has not been confirmed in a large RCT.

›How much did HRT prescribing drop after the WHI results?

U.S. HRT prescriptions fell approximately 50% between 2001 and 2003. Prescribing has partially recovered but remains well below pre-WHI levels, and many clinicians still avoid prescribing HRT even for clearly symptomatic patients.

›What did the long-term WHI follow-up show about mortality?

The 18-year cumulative follow-up found no significant difference in all-cause mortality or cardiovascular mortality between the CEE + MPA group and the placebo group, including the post-intervention period after women stopped taking the study medication.

References

• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002;288(3):321-333. PubMed
• Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465-1477. PubMed
• Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality. JAMA. 2017;318(10):927-938. PubMed
• The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. PubMed
• FDA. Prempro (conjugated estrogens/medroxyprogesterone acetate) prescribing information. FDA Label
• Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens (ESTHER study). Circulation. 2007;115(7):840-845. PubMed